NTx
NTx Bio develops automated, benchtop continuous-flow biomanufacturing platforms for RNA and protein production. The company applies cell-free synthetic biology and hollow-fiber continuous-flow reactors to produce high-integrity mRNA, self-amplifying RNA (saRNA), and proteins with linear scalability from milligram research quantities to gram-scale translational/clinical needs. NTx emphasizes closed, single-use workflows, real-time process monitoring, domestic sourcing of critical enzymatic components, and a pathway from research-use systems to GMP-capable platforms.
Industries
Nr. of Employees
medium (51-250)
Patents
Non-hierarchical infrastructure for managing twin-security keys of physical persons or of elements (IGCP/PKI)
US-9397839-B2
View Details
Non-hierarchical infrastructure for managing twin-security keys of physical persons or of elements (IGCP/PKI)
US-9397839-B2
View DetailsProducts
Benchtop continuous-flow RNA synthesis and purification system
Automated, compact continuous-flow system that performs IVT and initial purification in a single automated run, designed for research and scalable to translational volumes.
Benchtop recombinant cell-free protein expression system
Fully recombinant cell-free transcription–translation platform for producing proteins rapidly without extract-associated impurities.
Benchtop continuous-flow RNA synthesis and purification system
Automated, compact continuous-flow system that performs IVT and initial purification in a single automated run, designed for research and scalable to translational volumes.
Benchtop recombinant cell-free protein expression system
Fully recombinant cell-free transcription–translation platform for producing proteins rapidly without extract-associated impurities.
Services
Automated benchtop production and purification of mRNA/saRNA for research, translational programs, and personalized medicine workflows delivered as a service.
Fully recombinant, extract-free in vitro transcription–translation services for rapid protein production and process development.
Consulting to assist customers in transitioning research-use continuous-flow workflows to GMP-capable clinical manufacturing.
Automated benchtop production and purification of mRNA/saRNA for research, translational programs, and personalized medicine workflows delivered as a service.
Fully recombinant, extract-free in vitro transcription–translation services for rapid protein production and process development.
Consulting to assist customers in transitioning research-use continuous-flow workflows to GMP-capable clinical manufacturing.
Expertise Areas
- Continuous-flow RNA manufacturing
- Cell-free protein expression
- Benchtop biomanufacturing and scale-up
- Process development and translational workflows
Key Technologies
- Hollow-fiber continuous-flow bioreactors
- Continuous-flow in vitro transcription and coupled purification
- Cell-free synthetic biology
- Fully recombinant cell-free transcription–translation
News & Updates
Announcement of the formation of a Scientific Advisory Board with experts from major cancer centers to advise on RNA and protein manufacturing platforms.
Commercial launch of a benchtop continuous-flow IVT and purification system producing high-integrity RNA for research and translational applications.
Introduction of a flexible benchtop continuous-flow RNA production system designed for process development and translational workflows; RUO availability and planned GMP availability announced.
Announcement of a contract to demonstrate a rapidly deployable RNA vaccine production capability in collaboration with a clinical partner.
Report that the continuous-flow platform has been used to automate mRNA amplification of patient-derived tumor material for a personalized vaccine now dosing patients in a Phase 1 refractory melanoma trial.
Raised $47.5 million in Series B financing to advance next-generation biomanufacturing platforms.
Announcement of the formation of a Scientific Advisory Board with experts from major cancer centers to advise on RNA and protein manufacturing platforms.
Commercial launch of a benchtop continuous-flow IVT and purification system producing high-integrity RNA for research and translational applications.
Introduction of a flexible benchtop continuous-flow RNA production system designed for process development and translational workflows; RUO availability and planned GMP availability announced.
Announcement of a contract to demonstrate a rapidly deployable RNA vaccine production capability in collaboration with a clinical partner.
Report that the continuous-flow platform has been used to automate mRNA amplification of patient-derived tumor material for a personalized vaccine now dosing patients in a Phase 1 refractory melanoma trial.
Raised $47.5 million in Series B financing to advance next-generation biomanufacturing platforms.